Covaxin effective against Delta Variant: Top US health institute

India's Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, effectively neutralises both Alpha and Delta variants of coronavirus, the US' National Institute of Health has said. The NIH said results of two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India, respectively.

The NIH, which has a history of strong scientific collaboration with India, said that an adjuvant developed with funding from it has contributed to the success of the highly efficacious Covaxin.Adjuvants are substances formulated as part of a vaccine to boost immune responses and enhance a vaccine's effectiveness.Covaxin comprises a disabled form of SARS-CoV-2 that cannot replicate but still stimulates the immune system to make antibodies against the virus. Covaxin is safe and well-tolerated, according to the published results from a phase 2 trial of the vaccine. The NIH further said the safety data from a phase 3 trial of Covaxin will become available later this year.